Takeda

Takeda(TKPHF)

TOKYO, Japan
Pharmaceutical3 H-1B visas (FY2023)
WebsiteLinkedInCareers Page

Focus: Small Molecule, Enzymes

Takeda is a life sciences company focused on Small Molecule, Enzymes.

GI/GastroenterologyRare DiseasesNeuroscienceOncology
Funding Stage
PUBLIC
Employees
49,000
Open Jobs
0

Products & Portfolio (31)

19 discontinued products not shown

ACTOS
pioglitazone
LOE Approaching
ORAL · TABLET
action. ACTOS decreases insulin resistance in the periphery and in the liver resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output. Pioglitazone is not an insulin secretagogue. Pioglitazone is an agonist for peroxisome proliferator-activated receptor-gamma (PPARγ). PPAR receptors are found in tissues important for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of PPARγ nuclear receptors modulates the transcription of a number of insulin responsive genes involved in the control of glucose and lipid metabolism. In animal models of diabetes, pioglitazone reduces the hyperglycemia, hyperinsulinemia, and hypertriglyceridemia characteristic of insulin-resistant states such as type 2 diabetes. The metabolic changes produced by pioglitazone result in increased responsiveness of insulin-dependent tissues and are observed in numerous animal models of insulin resistance. Because pioglitazone enhances the effects of circulating insulin (by decreasing insulin resistance), it does not lower blood glucose in animal models that lack endogenous insulin.
type 2 diabetes mellitus in multiple clinical settingstype 2 diabetes mellitustype 1 diabetes+2 more
1999
30
ADDERALL XR 10
dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate
LOE Approaching
ORAL · CAPSULE, EXTENDED RELEASE
non-catecholamine sympathomimetic amines with CNS stimulant activity. The mode of therapeutic action in ADHD is not known.
attention deficit hyperactivity disorder (ADHD) in adultsolder
2001
30
ADDERALL XR 15
dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate
LOE Approaching
ORAL · CAPSULE, EXTENDED RELEASE
non-catecholamine sympathomimetic amines with CNS stimulant activity. The mode of therapeutic action in ADHD is not known.
attention deficit hyperactivity disorder (ADHD) in adultsolder
2001
30
ADDERALL XR 20
dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate
LOE Approaching
ORAL · CAPSULE, EXTENDED RELEASE
non-catecholamine sympathomimetic amines with CNS stimulant activity. The mode of therapeutic action in ADHD is not known.
attention deficit hyperactivity disorder (ADHD) in adultsolder
2001
30
ADDERALL XR 25
dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate
LOE Approaching
ORAL · CAPSULE, EXTENDED RELEASE
non-catecholamine sympathomimetic amines with CNS stimulant activity. The mode of therapeutic action in ADHD is not known.
attention deficit hyperactivity disorder (ADHD) in adultsolder
2001
30
ADDERALL XR 30
dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate
LOE Approaching
ORAL · CAPSULE, EXTENDED RELEASE
non-catecholamine sympathomimetic amines with CNS stimulant activity. The mode of therapeutic action in ADHD is not known.
attention deficit hyperactivity disorder (ADHD) in adultsolder
2001
30
ADDERALL XR 5
dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate
LOE Approaching
ORAL · CAPSULE, EXTENDED RELEASE
non-catecholamine sympathomimetic amines with CNS stimulant activity. The mode of therapeutic action in ADHD is not known.
attention deficit hyperactivity disorder (ADHD) in adultsolder
2001
30
AGRYLIN
anagrelide hydrochloride
LOE Approaching
ORAL · CAPSULE
unknown. In cell culture studies, anagrelide suppressed expression of transcription factors including GATA-1 and FOG-1 required for megakaryocytopoiesis, ultimately leading to reduced platelet production.
thrombocythemiasecondary to myeloproliferative neoplasmsto reduce the elevated platelet count+2 more
1997
30
ALUNBRIG
brigatinib
Peak
ORAL · TABLET
Tyrosine Kinase Inhibitors
lung cancerlymphoma
2017
0
CARBATROL
carbamazepine
LOE Approaching
ORAL · CAPSULE, EXTENDED RELEASE
Cytochrome P450 3A4 Inducers
the treatment of the pain associated with true trigeminal neuralgiaEpilepsy
1997
30
DEXILANT
dexlansoprazole
Peak
ORAL · CAPSULE, DELAYED RELEASE
Proton Pump Inhibitors
older for: Healing of all grades of erosive esophagitis (EE)older for healing of all grades of erosive esophagitis (EE) for up to eight weeksolder to maintain healing of EE+3 more
2009
0
DUETACT
pioglitazone and glimepiride
LOE Approaching
ORAL · TABLET
2 antihyperglycemic agents with different mechanisms of action to improve glycemic control in patients with type 2 diabetes: pioglitazone, a member of the thiazolidinedione class, and glimepiride, a member of the sulfonylurea class. Thiazolidinediones are insulin-sensitizing agents that act primarily by enhancing peripheral glucose utilization, whereas sulfonylureas are insulin secretagogues that act primarily by stimulating release of insulin from functioning pancreatic beta cells. Pioglitazone Pioglitazone is a thiazolidinedione that depends on the presence of insulin for its mechanism of action. Pioglitazone decreases insulin resistance in the periphery and in the liver resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output. Pioglitazone is not an insulin secretagogue. Pioglitazone is an agonist for peroxisome proliferator-activated receptor-gamma (PPARγ). PPAR receptors are found in tissues important for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of PPARγ nuclear receptors modulates the transcription of a number of insulin responsive genes involved in the control of glucose and lipid metabolism. In animal models of diabetes, pioglitazone reduces the hyperglycemia, hyperinsulinemia, and hypertriglyceridemia characteristic of insulin-resistant states such as type 2 diabetes. The metabolic changes produced by pioglitazone result in increased responsiveness of insulin-dependent tissues and are observed in numerous animal models of insulin resistance. Because pioglitazone enhances the effects of circulating insulin (by decreasing insulin resistance), it does not lower blood glucose in animal models that lack endogenous insulin. Glimepiride Glimepiride primarily lowers blood glucose by stimulating the release of insulin from pancreatic beta cells. Sulfonylureas bind to the sulfonylurea receptor in the pancreatic beta cell plasma membrane, leading to closure of the ATP-sensitive potassium channel, thereby stimulating the release of insulin.
type 2 diabetes mellitusglimepiride is appropriatetype 1 diabetes+2 more
2006
15
View all 31 products

Pipeline & Clinical Trials

90Second IBD
IBD
N/A
Clinical Trials (1)
NCT0568613590Second IBD for the Improvement of Self Efficacy and Quality of Life in Inflammatory Bowel Disease Patients
N/A
No Intervention
Dravet Syndrome (DS)
N/A
Clinical Trials (5)
NCT06405087A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Phase 3
NCT05442567A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Phase 3
NCT02528786Blood Sample Collection Study for Pharmacogenomic Characterization of Participants That Previously Received Namilumab in M1-1188-002-EM (PRIORA, [NCT01317797]) Study
Phase 1

+2 more

Pen and Paper Digit Symbol Substitution Test
Major Depressive Episode
N/A
Clinical Trials (1)
NCT03999567Validation Study: Mobile DSST on Cognition in Adults With MDD
N/A
continuous glucose monitoring
Diabetes Mellitus, Type 2
N/A
Clinical Trials (1)
NCT03487887Secondary Care - Continuous Glucose Monitoring
N/A
Freeze-dried live attenuated measles and rubella combined vaccine
Measles/Rubella
N/A
Clinical Trials (2)
NCT02151773Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Strain/TO-336 Strain) Special Drug Use Surveillance of Vaccinees After the First Vaccination
N/A
NCT02158364Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Strain/TO-336 Strain) Specified Drug-use Survey of Vaccinees After the Second Vaccination
N/A
N/A
Clinical Trials (5)
NCT03042325Safety and Efficacy of Alogliptin in Indian Participants With Type 2 Diabetes Mellitus
Phase 4
NCT02856113Phase 3 Alogliptin Pediatric Study
Phase 3
NCT00856284Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus
Phase 3

+2 more

No Intervention
Hypertension
N/A
Clinical Trials (1)
NCT02467855Epidemiological Study in Thai Participants With Hypertension
N/A
N/A
Clinical Trials (1)
NCT04869280Post-Marketing Study of Prucalopride Safety In Pregnancy
N/A
N/A
Clinical Trials (1)
NCT03219723Drug Use Surveillance of Takecab for "Supplement to Helicobacter Pylori Eradication"
N/A
A Study on Administration Choices of Vedolizumab and Outcomes for Adults With Inflammatory Bowel Dis
Inflammatory Bowel Diseases
N/A
Clinical Trials (1)
NCT04885920A Study on Administration Choices of Vedolizumab and Outcomes for Adults With Inflammatory Bowel Disease (IBD) (VARIETY - CROATIA AND SLOVENIA)
N/A
PEGylated Recombinant Factor VIII
Hemophilia A
N/A
Clinical Trials (5)
NCT02585960BAX 855 PK-guided Dosing
Phase 3
NCT01913405Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures
Phase 3
NCT02615691A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A
Phase 3

+2 more

A European Post-Authorisation Observational Study (Registry) of Patients With Chronic Adrenal Insuff
Chronic Adrenal Insufficiency
N/A
Clinical Trials (1)
NCT01661387A European Post-Authorisation Observational Study (Registry) of Patients With Chronic Adrenal Insufficiency (AI)
N/A
A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in Argentina
Angioedemas, Hereditary
N/A
Clinical Trials (1)
NCT04955964A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in Argentina
N/A
Intensive Pharmacovigilance Program for Elaprase (SHP ELA-701)
Hunter Syndrome
N/A
Clinical Trials (1)
NCT03582449Intensive Pharmacovigilance Program for Elaprase (SHP ELA-701)
N/A
N/A
Clinical Trials (1)
NCT06441578A Survey of Recombinant ADAMTS13 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
N/A
Prospective Observation of Cardiac Safety With Proteasome Inhibition
Heart Failure
N/A
Clinical Trials (1)
NCT02178579Prospective Observation of Cardiac Safety With Proteasome Inhibition
N/A
A Study on Vonoprazan in the Real-world Clinical Practice in China
Esophagitis Peptic
N/A
Clinical Trials (1)
NCT04501627A Study on Vonoprazan in the Real-world Clinical Practice in China
N/A
N/A
Clinical Trials (1)
NCT05735327A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETY
N/A
Leuprorelin acetate
Breast Cancer
N/A
Clinical Trials (1)
NCT02154139Leuprorelin Acetate SR 11.25 mg for Injection Specified Drug-use Survey "Long-term Use Survey on Premenopausal Breast Cancer Patients (96 Weeks)"
N/A
N/A
Clinical Trials (1)
NCT03981939Perianal Fistula (PAF) Validation and Burden of Illness Study
N/A
N/A
Clinical Trials (1)
NCT02024945Efficacy, Tolerability and Impact on Quality of Life of Propiverine in Patients With Overactive Bladder Syndrome
N/A
N/A
Clinical Trials (1)
NCT05489640A Study in Adults With Hereditary Angioedema (HAE) Who Currently Receive Icatibant at Home
N/A
Protein C Concentrate
Protein C Deficiency
N/A
Clinical Trials (3)
NCT01127529Ceprotin Treatment Registry
N/A
NCT00161720Retrospective Study to Capture Dosing and Treatment Outcome Data in Participants With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
N/A
NCT06590974A Study of Freeze-dried Human Protein C Concentrate (TAK-662) in Participants With Congenital Protein C Deficiency
N/A
The Myelin Disorders Biorepository Project
Leukodystrophy
N/A
N/A
Clinical Trials (1)
NCT00745030Efficacy and Tolerability of Ramelteon in Patients With Rapid Eye Movement (REM) Behavior Disorder and Parkinsonism
N/A
Portable EEG Device
Healthy Volunteers
N/A
Clinical Trials (1)
NCT04445129Wake and Sleep State Transitions on a Portable Electroencephalogram (EEG) Device in Narcolepsy Type 1 (NT1) and Healthy Participants
N/A
Octocog alfa
Hemophilia A
N/A
Clinical Trials (5)
NCT00916032Pharmacokinetic Study of ADVATE 3000 IU in Previously Treated Patients With Severe Hemophilia A
Phase 4
NCT02170402China ADVATE PTP Study
Phase 4
NCT02634723Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia A
N/A

+2 more

Remote monitoring tool
Inflammatory Bowel Diseases
N/A
Clinical Trials (1)
NCT04151420Real Life Remote Monitoring of Mild, Moderate and Severe Infectious Complications in IBD by Patient Reported Assessment
N/A
N/A
Clinical Trials (1)
NCT05137704A Study on the Use of Healthcare Resources and Costs of Attention Deficit Hyperactivity Disorder (ADHD) in Adults in England
N/A
N/A
Clinical Trials (5)
NCT05187208PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer
Phase 4
NCT03759587Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer
Phase 2
NCT04734665Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor
Phase 2

+2 more

T-cell Brazil: Prospective Collection of Data in T-cell Lymphomas Patients
T-cell Lymphoma
N/A
Clinical Trials (1)
NCT03207789T-cell Brazil: Prospective Collection of Data in T-cell Lymphomas Patients
N/A
Post Marketing Surveillance (PMS) Study for Velaglucerase Alfa (VPRIV) in India
Gaucher Disease
N/A
Clinical Trials (1)
NCT04429984Post Marketing Surveillance (PMS) Study for Velaglucerase Alfa (VPRIV) in India
N/A
Technochrom C1-INH Kit
Hereditary Angioedema (HAE)
N/A
Clinical Trials (1)
NCT07293364A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary Angioedema
N/A
N/A
Clinical Trials (3)
NCT02394795Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC
Phase 3
NCT02337946Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal Carcinoma
Phase 2
NCT02394834An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer
N/A
N/A
Clinical Trials (1)
NCT02958995Epidemiologic Study Of Diabetes And Cancer Risk
N/A
non-interventional retrospective epidemiological observational study
Secondary Immunodeficiencies (SID)
N/A
Clinical Trials (1)
NCT04172467Quality Assurance of Secondary Immunodeficiencies (SID) in CLL/MM Patients
N/A
N/A
Clinical Trials (1)
NCT04484363Expanded Access Program With Pevonedistat (Given With Azacitidine) for Adults With Higher-risk Myelodysplastic Syndromes
N/A
N/A
Clinical Trials (1)
NCT06346899A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China
N/A
A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America
Hereditary Angioedema (HAE)
N/A
Clinical Trials (1)
NCT03845400A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America
N/A
Agrylin Drug Use-Result Survey
Essential Thrombocythemia (ET)
N/A
Clinical Trials (1)
NCT03625895Agrylin Drug Use-Result Survey
N/A
A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real
Inflammatory Bowel Disease (IBD)
N/A
Clinical Trials (1)
NCT05384080A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Poland
N/A
N/A
Clinical Trials (1)
NCT03555591Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus"
N/A
Qualitative Interview - Participants/ Patients
Hemophilia B
N/A
Clinical Trials (1)
NCT03054389Non-Interventional Study to Capture the Patient Experience on Gene Therapy for Hemophilia Within the AskBio009-101 Study Through Patient and Investigator Interviews
N/A
N/A
Clinical Trials (4)
NCT00931918Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Phase 2
NCT03984097A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)
Phase 1
NCT02026505Evaluation of Cardiotoxic Effects of Bortezomib
N/A

+1 more

N/A
Clinical Trials (1)
NCT06750731Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention
N/A
A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II
Hereditary Angioedema (HAE)
N/A
Clinical Trials (1)
NCT04130191A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II
N/A
N/A
Clinical Trials (1)
NCT01945216Alogliptin Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Monotherapy/Combination Therapy With α-GI"
N/A
N/A
Clinical Trials (1)
NCT04887519A Study of Brigatinib to Treat Adults With Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non Small Cell Lung Cancer (NSCLC)
N/A
Effect of Stimulant Medication on Loss of Control Eating in Youth With Attention Deficit/Hyperactivi
Loss of Control Eating
N/A
Clinical Trials (1)
NCT05592119Effect of Stimulant Medication on Loss of Control Eating in Youth With Attention Deficit/Hyperactivity Disorder
N/A
A Study in Teenagers and Adults With Hereditary Angioedema (HAE) Type I or Type II Who Use Lanadelum
Hereditary Angioedema (HAE)
N/A
Clinical Trials (1)
NCT04861090A Study in Teenagers and Adults With Hereditary Angioedema (HAE) Type I or Type II Who Use Lanadelumab as Long-Term Prophylaxis
N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 82 approved products, 176 clinical trials
Top TAs: Oncology, Metabolic Diseases, Immunology
H-1B (2023): 3 approvals
Publications: 25 in PubMed
Portfolio Health
Pre-Launch1 (1%)
Growth4 (5%)
Peak18 (22%)
LOE Approaching48 (59%)
Post-LOE11 (13%)
82 total products
Therapeutic Area Focus
Oncology
6 marketed306 pipeline
Metabolic Diseases
9 marketed169 pipeline
Immunology
3 marketed150 pipeline
Rare Diseases
2 marketed111 pipeline
Gastroenterology
7 marketed84 pipeline
Neurology
1 marketed86 pipeline
Cardiovascular
3 marketed74 pipeline
Nephrology
2 marketed45 pipeline
Marketed
Pipeline

Visa Sponsorship

Sponsors Work Visas
H-1B Petitions (FY2023)
3
Approved
0
Denied
100%
Rate

Source: USCIS H-1B Employer Data Hub